Sharechat Logo

Pacific Edge secures patent for colorectal cancer detection technology

Wednesday 23rd June 2010

Text too small?

Pacific Edge Biotechnology has been awarded a New Zealand patent for its colorectal cancer prognostic technology.

The Dunedin-based company expects more late stage patents to be awarded in other targeted countries in the next two years for the technology, which enables the detection of aggressive cancer in patients already diagnosed with colorectal cancer.

The prognostic test enables physicians to predict colorectal cancer progression and provide patients with more specific treatment following surgery, said Pacific Edge's chief executive David Darling. The colorectal cancer prognostic gene signature is the company's second commercial product, joining its recently launched bladder detection test, Cxbladder.

Pacific Edge has developed a gene expression database from a range of human tumours which, along with a patient's clinical data, forms the discovery platform for diagnostic and prognostic biomarkers. Colorectal cancer is the fourth most common cancer, and in 2007 there were 1 million cases diagnosed worldwide with 520,000 dying of the disease.

Pacific Edge recently completed successful European clinical trials of the prognostic gene signature for colorectal cancer, demonstrating the technology's use in distinguishing between high and low risk patients.

"The early detection of those patients with an aggressive disease is a significant medical breakthrough," Darling said. "The Pacific Edge prognostic gene signature will provide clinicians with a valuable tool to help identify those patients at greatest risk, who will then be able to be targeted for adjuvant chemotherapy in addition to surgery."

Pacific Edge shares have gained one cent today to $0.24.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Pacific Edge shares soar to new record on optimism about potential US growth
Pacific Edge at record-high after signing 2nd US health provider network
Masfen, long-term Pacific Edge backer, sells 10 mln shares near record high
Pacific Edge sees $100M revenue from US in five years
Pacific Edge US lab complete, seeks regulatory approval
Pacific Edge bladder test validation bodes well for US sales
Pacific Edge signs Auckland distribution agreement for bladder test
Pacific Edge 1H loss narrows as company eyes US market for bladder test
Pacific Edge has pipeline of new products to follow new cancer-test patents